Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD5 CAR T cells

A preparation of allogeneic T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for CD5, with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-CD5 CAR T cells target and bind to CD5-expressing tumor cells, thereby inducing selective cytotoxicity in CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T cells and overexpressed on various B- and T-cell malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic anti-CD5 CAR-T cells allogeneic CD5-targeting CAR T cells donor-derived anti-CD5 CAR T cells donor-derived CD5 CAR T cells

allogeneic anti-CD5 CAR T cells

Search NCI's Drug Dictionary